Overview

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

Status:
Completed

Trial end date:
2018-12-03

Target enrollment:

Participant gender:

Summary

The purpose of this pharmacodynamic and pharmacokinetic study is to identify a dose of TV-46046 (within the range 80 to 300 mg) that is both safe and consistent with contraceptive effect when injected every 6 months.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products, R&D Inc.

Collaborator:

FHI 360

Treatments:

Medroxyprogesterone
Medroxyprogesterone Acetate